Hot Features
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, typ... Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein, recent acute coronary syndrome, and post COVID-19 conditions. The company has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; developing cardiovascular and pulmonary arterial hypertension indications; and Medison Pharma Ltd. The company is headquartered in Calgary, Canada. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.005 | -5.26315789474 | 0.095 | 0.095 | 0.09 | 62228 | 0.09014726 | CS |
| 4 | -0.005 | -5.26315789474 | 0.095 | 0.1 | 0.09 | 25850 | 0.09207803 | CS |
| 12 | -0.015 | -14.2857142857 | 0.105 | 0.11 | 0.085 | 27361 | 0.09703199 | CS |
| 26 | -0.01 | -10 | 0.1 | 0.135 | 0.085 | 31839 | 0.10479455 | CS |
| 52 | 0.05 | 125 | 0.04 | 0.3 | 0.04 | 72963 | 0.11515897 | CS |
| 156 | 0.01 | 12.5 | 0.08 | 0.3 | 0.035 | 65548 | 0.08533685 | CS |
| 260 | -0.75 | -89.2857142857 | 0.84 | 0.84 | 0.035 | 65297 | 0.17933232 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.